Molecular tools for targeted imaging and therapy of cancer

Journal of Molecular Recognition

Volumn 16, Issue 5, 2003, Pages 255-259

  Meares, Claude F ^a   Chmura, A J ^a   Orton, Molly S ^a   Corneillie, Todd M ^a   Whetstone, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Infinite affinity; Metal chelate; Nuclear imaging; Radiotherapy

Indexed keywords

ANIMALS; ANTIBODIES; AVIDIN; BIOTIN; HUMANS; METALS, RARE EARTH; NEOPLASMS; RADIOISOTOPES;

EID: 0141907728     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.634     Document Type: Article

References (30)

1. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su FM, Hobson LJ, Beaumier PL, Fritzberg AR. 2000. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl Acad. Sci. USA 97: 1802-1807.
2. Chinol M, Paganelli G, Sudati F, Meares C, Fazio F. 1997. Biodistribution in tumour-bearing mice of two Y-90-labelled biotins using three-step tumour targeting. Nucl. Med. Commun. 18: 176-182.
3. Chmura AJ, Orton MS, Meares CF. 2001. Antibodies with infinite affinity. Proc. Natl Acad. Sci. USA 98: 8480-8484.
4. Chmura AJ, Schmidt BD, Corson DT, Traviglia ST, Meares CF. 2002. Electrophilic chelating agents for binding of metal chelates to engineered antibodies. J. Controlled Release 78: 249-258.
5. Lentner C (ed.). 1998. Geigy Scientific Tables, Vol 3, Ciba-Geigy: Basel.
6. Corneillie TM, Whetstone PA, Fisher AJ, Meares CF. 2003. A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series. J. Am. Chem. Soc. 125: 3436-3437.
7. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human burkitt's lymphoma (Raji). Clin. Cancer Res. 3: 71-79.
8. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. 1997b. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl Acad. Sci. USA 94: 4000-4004.
9. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. 1998. Yttrium-90-DOTA-peptide chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J. Nucl. Med. 39: 842-849.
10. Fersht A. 1985. Enzyme Structure and Mechanism, 2nd edn. Freeman: New York, 1985; 56-63.
11. Goodwin DA, Meares CF. 1997. Pretargeting - general principles. Cancer 80(Suppl.): 2675-2680.
12. Goodwin DA, Meares CF, McTigue M, Chaovapong W, Diamanti CI, Ransone CH, McCall MJ. 1992. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nucl. Med. 33: 2006-2013.
13. Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI. 1994. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and Y-88-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in Balb/c mice with KHJJ mouse adenocarcinoma - a model For Y-90 radioimmunotherapy. Cancer Res. 54: 5937-5946.
14. Li M, Meares CF. 1993. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem. 4: 275-283.
15. Love R, Villafranca JE, Aust R, Nakamura K, Jue R, Radharkrishnan R, Butler W. 1993. How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate. Biochemistry 32: 10950-10959.
16. Meyer DL, Fineman M, Unger BW, Frincke JM. 1990. Kinetics of the dissociation of indium-(para-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogs from the monoclonal anti-hapten antibody CHA255. Bioconjugate Chem. 1: 278-284.
17. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. 1985. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem. 148: 249-253.
18. Moi MK, Meares CF, DeNardo SJ. 1988. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4, 7, 10-tetraazacyclododecane-N,-N′, N″, N‴-tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc. 110: 6266-6267.
19. Nicholson S, Gooden CSR, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF, Epenetos AA. 1998. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol. Repo. 5: 223-226.
20. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW. 2003. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101: 2340-2348.
21. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM. 1985. Antibodies against metal chelates. Nature 316: 265-268.
22. Robert B, Mach J-P, Mani J-C, Ychou M, Folli S, Artus J-C, Pelegrin A. 1996. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor. Cancer Res. 56: 4758-4765.
23. Rose LM, Gunasekera AH, Denardo SJ, Denardo GL, Meares CF. 1996. Lymphoma selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol. Immunother. 43: 26-30.
24. Rouvier E, Gautherot E, Meyer P, Barbet J. 1997. Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens: results and clinical perspectives. Hormone Res. 47: 163-167.
25. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM. 2003. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 63: 354-363.
26. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM. 1991. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 51: 6650-6655.
27. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. 1974. Chelating agents for the binding of metal ions to macromolecules. Nature 250: 587-588.
28. Taylor-Papadimitriou J, Epenetos AA. 1994. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol. 12: 227-233.
29. Yeh SM, Sherman DG, Meares CF. 1979. A new route to 'bifunctional' chelating agents: conversion of amino acids to analogs of ethylenedinitrilotetraacetic acid. Anal. Biochem. 100: 152-159.
30. Yuan F, Baxter LT, Jain RK. 1991. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res. 51: 3119-3130.